Holen Sie sich die Stockscreener-App
11.45
1.38%
-0.16
Vorhandelsmarkt:
11.45
Schlusskurs vom Vortag:
$11.61
Offen:
$11.59
24-Stunden-Volumen:
604.19K
Relative Volume:
0.99
Marktkapitalisierung:
$691.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.99M
KGV:
-5.3512
EPS:
-2.1397
Netto-Cashflow:
$-79.92M
1W Leistung:
+4.28%
1M Leistung:
-62.20%
6M Leistung:
-42.29%
1J Leistung:
-40.49%
1-Tages-Spanne:
$11.10
$11.65
1-Wochen-Bereich:
$10.80
$11.67
52-Wochen-Spanne:
$10.52
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Compare OCS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
11.45 | 701.11M | 0 | -117.99M | -79.92M | -2.1397 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | JP Morgan | Overweight |
| 2025-08-27 | Eingeleitet | Needham | Buy |
| 2023-12-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-10-05 | Eingeleitet | Stifel | Buy |
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Oculis executive Sylvia Cheung reports June 10 share purchase - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment - Streetwise Reports
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles - AOL.com
OCS News | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Oculis shelves FDA filing after phase 3 DME trials miss key vision goals - MSN
Oculis enrolls first patient in licaminlimab PREDICT-1 DED trial - Optometry Times
Oculis to present neuroprotective drug Privosegtor at Clinical Trials Summit 2026 - Pluang
Oculis to present Privosegtor's progress for optic neuritis treatment at Clinical Trials Summit 2026 - Pluang
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm - PR Newswire
H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com UK
H.C. Wainwright reiterates Oculis stock rating on trial start By Investing.com - Investing.com Australia
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - The Manila Times
Oculis Holding AG to Present on Privosegtor at Clinical Trials at the Summit 2026 - Quiver Quantitative
Experimental eye drug Privosegtor aims to protect vision in optic neuritis - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Oculis Holding AG (OCS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Oculis executive and board member buys more company shares - Stock Titan
Oculis randomizes first patient in precision dry eye disease trial - grafa.com
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease - The Manila Times
New dry eye trial tailors licaminlimab to genes; only 13% see sustained relief - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Oculis to present updates on late-stage eye disease treatments at Goldman Sachs Healthcare Conference - Pluang
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference - The Manila Times
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud I - GuruFocus
Oculis Holding AG to Provide Update on Late-Stage Portfolio at 47th Annual Goldman Sachs Global Healthcare Conference - Quiver Quantitative
Price-Driven Insight from (OCS) for Rule-Based Strategy - Stock Traders Daily
2026-06-08 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Investors to Learn More About the Investigation | NDAQ:OCS | Press Release - Stockhouse
Oculis Holding AG (OCS) Securities Fraud InvestigationLevi & Korsinsky - Morningstar
Nan Fung Group Cuts Oculis Stake Amid Phase 3 Trial Failure and Stock DeclineNews and Statistics - IndexBox
Lost Money on Oculis Holding AG (OCS)? Contact Levi & Korsinsky About Investigation - TMX Newsfile
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Gross - The National Law Review
2026-06-07 | Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:OCS | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Oculis Holding AG (OCS) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Oculis Holding AG (OCS) And Encourages Stockholders to Reach Out | NDAQ:OCS | Press Release - Stockhouse
Oculis Holding (OCS) Is Down 60.1% After OCS-01 Trial Failure And Pipeline Pivot – Has The Bull Case Changed? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Stockholders to Connect - ACCESS Newswire
OCS Stock Price and Chart — NASDAQ:OCS - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AGOCS - PR Newswire
Levi & Korsinsky Announces Investigation of Securities Claims Against Oculis Holding AG (OCS) - GlobeNewswire
OCS Maintained by JP Morgan -- Price Target Lowered to $23.00 - GuruFocus
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-03 | Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:OCS | Press Release - Stockhouse
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud - Business Wire
OCS Maintains by Baird -- Price Target Lowered to $38.00 - GuruFocus
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):